Sarepta Therapeutics shares tank as hopes for new drug approval fade
January 15, 2016 at 11:32 AM EST
Documents released by the FDA ahead of a meeting next week hint at rejection of Sarepta’s treatment for Duchenne muscular dystrophy.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.